Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The intranasal treatment, originally marketed in 2020, will now be available for patients with acute repetitive seizures as young as 2 years old.

FDA Expands Diazepam Nasal Spray Indication to Treat Ages 2 to 5

Videos

The professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, gave clinical insights on efforts to refine neuropsychological outcome measures for individuals with Down syndrome at risk for Alzheimer disease. [WATCH TIME: 3 minutes]

Adapting Cognitive Tools for Clinical Trials in Down Syndrome: Elizabeth Head, PhD

Beth Stein, MD, director of neuromuscular diseases at St. Joseph’s Health, shared insights on the impact of a newly approved pre-filled syringe formulation of efgartigimod, highlighting its potential to transform care delivery.

NeuroVoices: Beth Stein, MD, on Implications of Newly Approved Pre-Filled Syringe Option for Efgartigimod

CT-132, an approach that aims to reduce brain hypersensitivity, becomes the first marketed digital treatment for preventive migraine, intended to be used with other previously approved medications.

FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine

Nancy Glickenhaus Pier Professor of Pediatric Neuropsychiatry, Department of Neurology, NYU Grossman School of Medicine

The director of NYU Langone's Multiple Sclerosis Comprehensive Care Center discussed the importance of early, high-efficacy treatment for pediatric MS. [WATCH TIME: 3 minutes]

Advancements and Challenges in Pediatric Multiple Sclerosis Treatment: Lauren B. Krupp, MD

Senior director of mission programs at The ALS Association.

The senior director of mission programs at The ALS Association discussed how the thinkALS Toolkit can aid general neurologists in identifying and referring suspected cases more efficiently. [WATCH TIME: 5 minutes]

Improving Timely ALS Diagnosis With the thinkALS Toolkit: Melody Schaeffer, PhD, MPH

, has been with the team since September 2022. Follow her on Twitter 

The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs.  [WATCH TIME: 3 minutes]

Building Community and Education Through the AMDAPP CME Conference: Kinsey McCartney, PA-C

Staff neurologist, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic

Experts discussed recent advancements in diagnostic criteria, imaging techniques, and the evolving understanding of multiple sclerosis subtypes and treatment responses. [WATCH TIME: 10 minutes]

Key Insights from ACTRIMS Forum 2025: Diagnostic Criteria, Imaging, and MS Subtypes

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAN 2025

AD/PD 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

AAN 2020: Multiple Sclerosis Treatment Considerations

Multiple Sclerosis and Risk of COVID-19

Disease-Modifying Therapies for MS During COVID-19

AAN 2020: Real-World Data on Cladribine Tablets for MS

Multiple Sclerosis: Takeaways From AAN 2020

MS Treatment Optimization During COVID-19

Treating Patients With MS During the COVID-19 Pandemic

AAN 2020 Data Release: Ofatumumab for Relapsing MS

Novel Oral Therapy for MS: AAN Data Updates

The Future of Multiple Sclerosis Management

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

The Special Reports video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases. It also includes the RX Reports bonus series, which focuses on new therapeutics and FDA approvals.